Takeda Says FDA Approves Treatment for Colorectal Cancer
By Stephen Nakrosis
Pharmaceutical company Takeda said Wednesday that the U.S. Food and Drug Administration approved Fruzaqla as a treatment for certain patients with colorectal cancer.
Fruzaqla, or fruquintinib, an oral targeted therapy, was approved for adults with metastatic colorectal cancer who had received certain previous treatments for the condition.
The company said Fruzaqla and best supportive care showed "significant improvements in overall survival, with corresponding improvements in progression free survival, versus placebo plus best supportive care in two Phase 3 clinical trials."
Data from the trials supported an EU marketing authorization application for fruquintinib, "which was validated and accepted for review by the European Medicines Agency in June," Takeda said. A submission was made in September to the Japan Pharmaceuticals and Medical Devices Agency, the company said.
Write to Stephen Nakrosis at stephen.nakrosis@wsj.com
(END) Dow Jones Newswires
November 08, 2023 18:34 ET (23:34 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
After Earnings, Is Albemarle Stock a Buy, a Sell, or Fairly Valued?
-
Is ServiceNow Stock a Buy After Earnings and Its Investor Day?
-
3 Stocks to Buy and 3 Stocks to Sell After Earnings
-
Markets Brief: Is It Really a Surprising Quarter for Earnings?
-
After Earnings, Is Berkshire Hathaway Stock a Buy, a Sell, or Fairly Valued?
-
For Bond Investors, Delayed Rate Cuts Demand a Different Playbook
-
What’s Happening In the Markets This Week
-
How the Tokyo Stock Exchange Is Pushing for Better Shareholder Returns
-
Arm Earnings: Shares Fall as 2025 Guidance Disappoints Investors
-
Occidental Earnings: CrownRock Transaction Should Still Close, but Not Until the Third Quarter
-
After Earnings, Is Apple Stock a Buy, a Sell, or Fairly Valued?
-
Uber Earnings: Network Effect Continues to Drive Profitable Growth for Uber
-
Undervalued by 28%, This Stock Is a Buy for Patient Investors
-
10 Best Growth Stocks to Buy for the Long Term
-
The Best Technology Stocks to Buy
-
After Earnings, Is Coke Stock a Buy, a Sell, or Fairly Valued?